This episode features Ben Holmes, CEO and Co-founder of Nanochon, a medical device company focused on revolutionizing cartilage repair. The discussion highlights the significant challenges faced by patients with cartilage damage, including limited treatment options and the potential for further joint degeneration.

Nanochon is developing a groundbreaking 3D-printed implant designed to mimic the natural structure and function of cartilage. This innovative device is designed to be minimally invasive and easily implanted, offering a potential solution for patients facing cartilage damage and potentially delaying or even preventing the need for knee replacement surgery.

Ben shares insights into Nanochon's development progress, including upcoming human trials and their recent move to LaunchPort in Baltimore, a unique incubator space that provides access to state-of-the-art manufacturing facilities for medtech startups. With team expansion plans on the horizon, this story is fueled with insights, sure to leave you informed and inspired.

This episode discusses a huge unmet need in the medical device space: treatment for mixed urinary incontinence. Millions of patients, primarily women, suffer from this condition, and there is no effective treatment on the market. Current treatment options leave care gaps and patients resorting to over-the-counter products for symptom management.

Juniper Biomedical is a company that is developing a new type of treatment for mixed urinary incontinence. They are developing a unique neuromodulation micro implant that can be implanted with a minimally invasive procedure to deliver a very precise therapy. This has the potential to solve the problems of mixed incontinence, eliminate issues with inaccurate diagnosis, and importantly, provide a solution that patients are more likely to accept.

CEO and co-founder, David Constantine joins us to discuss their exciting progress, from extensive preclinical studies, to upcoming clinical trials. After a year of multiple highlights, including award winning on the stage of Medtech Innovator, the future looks bright for Juniper Biomedical. Their technology has the potential to make a real difference in the lives of millions of patients with pelvic health conditions, a story sure to leave you, informed and inspired.

This episode features Dave Rosa, CEO of NeuroOne, a company leading the way in innovative solutions for various neurological disorders. The discussion highlights the significant challenges faced by patients with epilepsy, particularly those whose condition is resistant to medication. Traditional treatment often involves multiple invasive surgeries, placing a significant physical and emotional burden on patients.

NeuroOne has developed a groundbreaking technology that integrates both diagnostic and therapeutic functions into a single device. This innovative approach enables physicians to identify the source of seizures and then immediately proceed with ablation of the affected brain tissue within a single surgical procedure, minimizing patient discomfort and hospital stays.

We explore the strategic partnership with Zimmer Biomet that has been pivotal for NeuroOne's successful market access, helping accelerate commercialization. With additional data insights, and future pharma collaboration opportunities, the future is truly bright for Dave and the team. NeuroOne is helping advance the movement towards personalized medicine, offering hope for improved patient outcomes, a story sure to leave you informed and inspired.